Press-release for stocks related to pharm-country for SNYNF

tags : Pharm-country symbols : SNYNF

save search

Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plus™, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)
Published: 2024-04-23 (Crawled : 00:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 1.7% | O: 1.7% H: 0.0% C: 0.0%
first drug authorized food depression treatment clearance for therapeutics

AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 08:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 0.13% | O: 1.17% H: 0.0% C: 0.0%
lung drug cancer treatment application therapeutics

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| 1.25% | O: -0.35% H: 0.0% C: 0.0%
TEVA | $13.01 -0.68% 7.5M

Health Technology

| 34.26% | O: -0.52% H: 3.73% C: 1.87%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 0.99% | O: -1.09% H: 0.0% C: 0.0%
disease treatment collaboration teva deal

DarioHealth Reports Third Quarter 2023 Financial and Operating Results
Published: 2023-11-02 (Crawled : 11:00) - biospace.com/
AMWL | $0.5338 -1.62% 0.0% 2.6M

Technology Services

| -54.24% | O: -6.78% H: 22.73% C: 21.82%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 3.11% | O: 3.0% H: 0.0% C: 0.0%
DRIO | $1.51 4.14% 3.97% 40K

Health Technology

| 43.56% | O: -26.73% H: 36.49% C: 36.49%
financial results

Merck Announces Third-Quarter 2023 Financial Results
Published: 2023-10-26 (Crawled : 11:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M

Health Technology

| 22.44% | O: -0.51% H: 4.0% C: 2.38%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -11.36% | O: 0.09% H: 0.0% C: 0.0%
MRNA | News S | $108.82 0.86% 0.85% 3.4M

Health Technology

| 40.55% | O: -0.04% H: 0.64% C: -0.98%
merck financial results

JDRF Encouraged by Results of PROTECT Clinical Trial
Published: 2023-10-18 (Crawled : 20:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -13.51% | O: -1.23% H: 0.0% C: 0.0%
trial results

Techdow USA Announces Launch of its Generic Lovenox®, (Enoxaparin Sodium – Preservative Free) in Prefilled Syringes
Published: 2023-06-08 (Crawled : 13:20) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -8.32% | O: -0.37% H: 0.94% C: 0.78%
lovenox usa

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
Published: 2023-05-01 (Crawled : 11:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -11.88% | O: 4.08% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -13.75% | O: -1.21% H: 0.0% C: 0.0%
OVID | $3.165 -1.09% -1.11% 110K

Health Technology

| -10.61% | O: -1.4% H: 3.4% C: 2.83%
MGTX | $4.87 -1.22% -1.23% 110K

Health Technology

| -7.85% | O: -0.75% H: 4.52% C: 2.82%
collaboration therapeutics

BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer
Published: 2023-04-24 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -16.64% | O: -0.22% H: 0.0% C: 0.0%
BCLI A | $0.5339 1.7% 1.67% 190K

Health Technology

| -82.62% | O: 1.31% H: 9.16% C: -1.29%
cell medical therapeutics

Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
Published: 2023-03-23 (Crawled : 08:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -3.5% | O: 5.54% H: 0.96% C: 0.96%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -3.61% | O: 6.53% H: 0.56% C: -0.54%
REGN | News | $906.55 -0.09% -0.08% 370K

Health Technology

| 20.77% | O: 7.34% H: 0.77% C: -0.53%
dupixent copd trial potential

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Published: 2023-03-21 (Crawled : 08:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -1.82% | O: 1.74% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -1.61% | O: 2.13% H: 0.0% C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K

Health Technology

| 19.5% | O: 0.71% H: 0.05% C: -0.64%
dupixent children six dermatitis approved

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
Published: 2023-03-21 (Crawled : 08:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -1.82% | O: 1.74% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -1.61% | O: 2.13% H: 0.0% C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K

Health Technology

| 19.5% | O: 0.71% H: 0.05% C: -0.64%
dupixent children six dermatitis approved

Ajax Therapeutics Appoints Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development
Published: 2023-03-09 (Crawled : 13:20) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -1.12% | O: 0.22% H: 0.1% C: -1.36%
preclinical therapeutics

Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
Published: 2023-03-07 (Crawled : 07:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -1.4% | O: 0.65% H: 0.0% C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K

Health Technology

| 16.27% | O: 0.21% H: 0.2% C: -1.04%
dupixent treatment fda urticaria application review

Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
Published: 2023-02-23 (Crawled : 19:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -2.05% | O: 0.91% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -1.94% | O: -0.98% H: 0.0% C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K

Health Technology

| 21.29% | O: -0.44% H: 2.71% C: 1.99%
treatment fda macular review diabetic

John Reed Jumps Ship at Sanofi to Helm J&J's R&D
Published: 2023-02-14 (Crawled : 16:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M

Health Technology

| -8.04% | O: -0.01% H: 0.14% C: -0.43%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 0.36% | O: 1.28% H: 0.0% C: 0.0%
sanofi

Ex-Sanofi R&D Chief to Helm J&J's R&D
Published: 2023-02-14 (Crawled : 14:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M

Health Technology

| -8.04% | O: -0.01% H: 0.14% C: -0.43%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 0.36% | O: 1.28% H: 0.0% C: 0.0%

Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
Published: 2023-02-02 (Crawled : 14:00) - biospace.com/
ALPMY | News | $9.49 -1.11% 480K

Manufacturing